BrainsWay Ltd.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BrainsWay Ltd. provides advanced non-invasive neurostimulation therapies for mental health conditions to markets including the United States, Europe, and Israel. The company's primary offering is its Deep Transcranial Magnetic Stimulation (Deep TMS) platform, which employs proprietary H-coil technology to stimulate deeper and broader brain regions. This innovative approach is utilized for several FDA-cleared indications, specifically major depressive disorder, including cases with co-occurring anxiety, obsessive-compulsive disorder, and smoking addiction. Recently, the Deep TMS system received expanded FDA clearance for major depressive disorder in adolescents aged 15 to 21, making it the only TMS device approved across this broad age range. Furthermore, an accelerated Deep TMS protocol for major depressive disorder has been cleared, significantly shortening the acute treatment phase. BrainsWay serves psychiatrists, hospitals, and medical centers, delivering its systems through both sales and a recurring revenue leasing model. The company, established in 2003 and headquartered in Jerusalem, Israel, is actively expanding its market reach through strategic investments in U.S. mental health providers and by exploring at-home neuromodulation solutions and new indications like alcohol use disorder.
Company News
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™
Analyzing Brainsway (NASDAQ:BWAY) and Green Thumb Industries (OTCMKTS:GTBIF)
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
Brainsway (BWAY) Upgraded to Buy: Here's Why
Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Receives $16.95 Average Target Price from Brokerages
Brainsway Q2 Earnings Call Highlights
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem
Brainsway (NASDAQ:BWAY) Sets New 52-Week High – Here’s What Happened
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
BrainsWay Announces Strategic Investment in Radial Health, Inc.
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Best Momentum Stocks to Buy for July 14th
New Strong Buy Stocks for July 14th
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
BrainsWay Announces Minority-Stake Investment in Hopemark Health